Astellas Pharma Inc.

Company Overview

Astellas Pharma Inc. is a global pharmaceutical company headquartered in Tokyo, Japan, with commercial operations and subsidiaries spanning North America, Europe, the Asia-Pacific region, and select emerging markets. It is focused on innovative prescription medicines across specialty therapeutic areas, including urology, oncology, immunology, neuroscience, and transplant medicine. Within the CKD market, Astellas’ primary involvement is through its transplantation and immunology segment, where it plays a critical role in managing advanced CKD and end-stage renal disease (ESRD) patients undergoing kidney transplantation. Its immunosuppressive therapies, including Prograf (tacrolimus) and Advagraf/Astagraf XL, are widely established as standard-of-care treatments for preventing organ rejection and improving long-term graft survival, positioning Astellas as a key pharmaceutical partner in renal transplantation.

Astellas has a regional access across North America (U.S. and Canada), Europe (including Germany, the U.K., France, and Switzerland), Asia-Pacific (Japan, China, South Korea, and Southeast Asia), and selected emerging markets in Latin America and the Middle East. Its global headquarters is in Tokyo, Japan, while key regional headquarters and R&D centers in the United States and Europe support regulatory engagement, clinical development, and commercialization.

Financial Highlights (FY 2025)

Company's Business Segments

• XTANDI : This product is used for the treatment of Prostate Cancer.
• PROGRAF : This medicine used to help prevent organ rejection for patients who have had a Kidney, Liver, Heart, Lung Transplant.
• PADCEV : Betanis tablet used for the Treatment for OAB. Betmiga and MYRBETRIQ is used to treat the symptoms of an Overactive Bladder.
• Other : Other segment includes all other medicines.